Cargando…
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stem from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical trials results...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543012/ https://www.ncbi.nlm.nih.gov/pubmed/37790427 http://dx.doi.org/10.1101/2023.09.22.559005 |
_version_ | 1785114207969083392 |
---|---|
author | Dureja, Chetna Rutherford, Jacob T. Pavel, Fahad B. A. Norseeda, Krissada Prah, Isaac Sun, Dianqing Hevener, Kirk E. Hurdle, Julian G. |
author_facet | Dureja, Chetna Rutherford, Jacob T. Pavel, Fahad B. A. Norseeda, Krissada Prah, Isaac Sun, Dianqing Hevener, Kirk E. Hurdle, Julian G. |
author_sort | Dureja, Chetna |
collection | PubMed |
description | Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stem from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical trials results for recent antibiotic candidates, underscore the urgent need for novel CDI antibiotics. To this end, we investigated C. difficile enoyl ACP reductase (CdFabK), a crucial enzyme in de novo fatty acid synthesis, as a drug target for microbiome-sparing antibiotics. To test this concept, we evaluated the efficacy and in vivo spectrum of activity of the phenylimidazole analog 296, which is validated to inhibit intracellular CdFabK. Against major CDI-associated ribotypes 296 had an MIC(90) of 2 μg/ml, which was comparable to vancomycin (1 μg/ml), a standard of care antibiotic. In addition, 296 achieved high colonic concentrations and displayed dosed-dependent efficacy in mice with colitis CDI. Mice that were given 296 retained colonization resistance to C. difficile and had microbiomes that resembled the untreated mice. Conversely, both vancomycin and fidaxomicin induced significant changes to mice microbiomes, in a manner consistent with prior reports. CdFabK therefore represents a potential target for microbiome-sparing CDI antibiotics, with phenylimidazoles providing a good chemical starting point for designing such agents. |
format | Online Article Text |
id | pubmed-10543012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-105430122023-10-03 In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy Dureja, Chetna Rutherford, Jacob T. Pavel, Fahad B. A. Norseeda, Krissada Prah, Isaac Sun, Dianqing Hevener, Kirk E. Hurdle, Julian G. bioRxiv Article Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stem from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical trials results for recent antibiotic candidates, underscore the urgent need for novel CDI antibiotics. To this end, we investigated C. difficile enoyl ACP reductase (CdFabK), a crucial enzyme in de novo fatty acid synthesis, as a drug target for microbiome-sparing antibiotics. To test this concept, we evaluated the efficacy and in vivo spectrum of activity of the phenylimidazole analog 296, which is validated to inhibit intracellular CdFabK. Against major CDI-associated ribotypes 296 had an MIC(90) of 2 μg/ml, which was comparable to vancomycin (1 μg/ml), a standard of care antibiotic. In addition, 296 achieved high colonic concentrations and displayed dosed-dependent efficacy in mice with colitis CDI. Mice that were given 296 retained colonization resistance to C. difficile and had microbiomes that resembled the untreated mice. Conversely, both vancomycin and fidaxomicin induced significant changes to mice microbiomes, in a manner consistent with prior reports. CdFabK therefore represents a potential target for microbiome-sparing CDI antibiotics, with phenylimidazoles providing a good chemical starting point for designing such agents. Cold Spring Harbor Laboratory 2023-09-22 /pmc/articles/PMC10543012/ /pubmed/37790427 http://dx.doi.org/10.1101/2023.09.22.559005 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Dureja, Chetna Rutherford, Jacob T. Pavel, Fahad B. A. Norseeda, Krissada Prah, Isaac Sun, Dianqing Hevener, Kirk E. Hurdle, Julian G. In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
title | In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
title_full | In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
title_fullStr | In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
title_full_unstemmed | In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
title_short | In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
title_sort | in vivo evaluation of clostridioides difficile enoyl-acp reductase ii (fabk) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543012/ https://www.ncbi.nlm.nih.gov/pubmed/37790427 http://dx.doi.org/10.1101/2023.09.22.559005 |
work_keys_str_mv | AT durejachetna invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT rutherfordjacobt invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT pavelfahadba invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT norseedakrissada invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT prahisaac invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT sundianqing invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT hevenerkirke invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy AT hurdlejuliang invivoevaluationofclostridioidesdifficileenoylacpreductaseiifabkinhibitionbyphenylimidazoleunveilsapromisingnarrowspectrumantimicrobialstrategy |